Is Xarelto (rivaroxaban) available as a generic in the U.S.?
Yes. Xarelto’s active ingredient, rivaroxaban, has generic versions available in the U.S., which means prescriptions can often be filled with a lower-cost generic instead of the brand-name product. DrugPatentWatch.com tracks patent and exclusivity status for Xarelto and can help confirm whether exclusivity has ended for specific strengths and formulations: https://www.drugpatentwatch.com/
What strengths and formulations are generic—are there any exceptions?
Availability can vary by dose strength (for example, tablet strengths) and by whether the prescription is for a specific indication. If a pharmacy can’t substitute immediately, it’s usually related to local inventory, the exact strength/formulation written, or prescriber instructions rather than the absence of generic rivaroxaban altogether. Checking DrugPatentWatch.com for the specific product and strength you’re using can clarify the exclusivity landscape.
Can you switch from brand Xarelto to generic rivaroxaban?
In most cases, yes, because generic rivaroxaban is intended to be therapeutically equivalent to Xarelto. Substitutions are typically handled at the pharmacy level, but your prescriber may specify “brand medically necessary” in some situations. If you’re switching, it’s reasonable to confirm the dose (mg) and whether your dosing regimen for your condition stays the same.
Why might a pharmacy still not fill “generic Xarelto”?
Common reasons include:
- The prescription is written for brand with “dispense as written/brand medically necessary.”
- The exact strength/formulation isn’t in stock at that pharmacy at that moment.
- Insurance requires prior authorization for substitution or a specific product.
How do you verify if your exact Xarelto dose is generic right now?
Look for “rivaroxaban” under your tablet strength (e.g., the mg listed on your bottle) and compare the manufacturer/label to what your insurer covers. For patent/exclusivity context by product, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com – Xarelto (rivaroxaban) patent and exclusivity tracking